Table 1.
Income group* | Country | Study population | Study design | Sample size and study | ||
---|---|---|---|---|---|---|
Newcastle–Ottawa scale score† | ||||||
HQ | MQ | LQ | ||||
Patient delay | ||||||
LIC | Ethiopia | People with TB | Cross-sectional | 216[24], 296[25], 360[26], 382[27], 398[28], 425[29], 605[30], 706[31], 924[32] | 129[33], 201[34], 226[35] | |
People with presumptive TB | Case–control | 838[36] | ||||
Cross-sectional | 476[37], 843[38], 1006[39] | 663[40], 763[41] | ||||
Mozambique | People with TB | Cross-sectional | 622[42] | |||
Tanzania | People with TB | Cross-sectional | 639[43] | 206[44] | ||
People with presumptive TB | Cross-sectional | 3388[45] | ||||
LMIC | Angola | People with TB | Cross-sectional | 385[46] | ||
Bangladesh | People with TB | Cross-sectional | 7280[47] | |||
Cambodia | People with TB | Mixed-methods | 96[48] | |||
India | People with TB | Cross-sectional | 216[49], 234[50] | 150[51], 261[52] | ||
People with TB (children) | Cross-sectional | 175[53] | ||||
People with presumptive TB | Cross-sectional | 437[54] | ||||
Indonesia | People with presumptive TB | Cross-sectional | 194[55] | 746[56] | ||
Kenya | People with TB | Cross-sectional | 230[57] | |||
People with presumptive TB | Cross-sectional | 426[58] | ||||
Nigeria | People with TB | Cross-sectional | 160[59], 450[60] | 102[61] | ||
Zambia | People with presumptive TB | Cross-sectional | 6708[62] | |||
Zimbabwe | People with TB | Cross-sectional | 383[63] | |||
UMIC | Brazil | People with TB | Cross-sectional | 139[64], 153[65] | 97[66], 101[67], 199[68], 218[69], 304[70] | |
TB-HIV co-infection | Prospective cohort | 201[71] | ||||
China | People with TB | Cross-sectional | 314[72], 1126[73], 2280[74] | 146[75], 259[76], 314[77], 323[78], 819[79], 1083[80] | ||
Prospective cohort | 202[81] | |||||
Retrospective cohort | 4677[82], 10356[20] | 75401[21] | ||||
People with presumptive TB | Cross-sectional | 1005[83] | ||||
Russia | People with TB | Cross-sectional | 105[84] | |||
South Africa | General population | Cross-sectional | 1020[85] | |||
People with presumptive TB | Cross-sectional | 104[86] | ||||
TB-HIV co-infection | Prospective cohort | 891[87] | ||||
Thailand | People with TB | Cross-sectional | 443[88] | 199[89] | ||
Health system delay | ||||||
LIC | Ethiopia | People with TB | Cross-sectional | 201[34] | ||
Nigeria | People with TB | Cross-sectional | 470[90] | |||
LMIC | Angola | People with TB | Cross-sectional | 385[46] | ||
UMIC | Brazil | People with TB | Cross-sectional | 218[69], 304[70], 305[91] | ||
China | People with TB | Cross-sectional | 314[72] | 146[75] | ||
Prospective cohort | 202[81] | |||||
Retrospective cohort | 4677[82] | |||||
South Africa | TB-HIV co-infection | Cross-sectional | 480[92] | |||
Treatment delay | ||||||
LIC | Tanzania | People with TB | Cross-sectional | 1161[93] | ||
LMIC | Bangladesh | People with TB | Cross-sectional | 123[94] | ||
Cambodia | People with TB | Mixed-methods | 96[48] | |||
India | People with TB | Cross-sectional | 234[50], 344[95] | 150[51] | ||
Mixed-methods | 2027[96] | |||||
Retrospective cohort | 662[97], 1800[98] | |||||
Zimbabwe | People with TB | Retrospective cohort | 2443[99] | |||
UMIC | China | People with TB | Cross-sectional | 314[100] | ||
Retrospective cohort | 4677[82] | |||||
South Africa | People with TB | Cross-sectional | 210[101] | |||
Total delay | ||||||
LIC | Ethiopia | People with TB | Cross-sectional | 216[24], 296[25], 328[102], 382[27] | 201[34] | |
Mozambique | People with TB | Cross-sectional | 622[42] | |||
Tanzania | People with TB | Cross-sectional | 206[44] | |||
LMIC | Bangladesh | People with TB | Cross-sectional | 7280[47] | ||
India | People with TB | Cross-sectional | 216[49], 289[103] | |||
Retrospective cohort | 656[104] | |||||
Indonesia | People with TB | Cross-sectional | 1116[105] | |||
Nigeria | People with TB | Cross-sectional | 450[60] | |||
Pakistan | People with TB | Cross-sectional | 844[106] | 252[107], 269[108] | ||
UMIC | Brazil | People with TB | Case–control | 242[109] | ||
Cross-sectional | 304[70] | |||||
South Africa | People with TB | Cross-sectional | 210[101] | |||
TB-HIV co-infection | Prospective cohort | 891[87] | ||||
Thailand | People with TB | Cross-sectional | 443[88] |
Income group* | Country | Study population | Methods of analysis | Study and sample size | ConQual rating‡ | CASP score§ |
---|---|---|---|---|---|---|
Qualitative studies | ||||||
LIC | Ethiopia | People with TB, contacts of people with TB, and health care workers |
Phenomenological analysis |
5 IDIs and 2 FGDs [110] | HQ | HQ |
People with TB | Thematic analysis | 26 IDIs [111] | HQ | HQ | ||
People with TB and policymakers | Thematic analysis | 19 IDIs [112] | HQ | HQ | ||
Mozambique | Caretakers of people with TB | Content analysis | 35 IDIs [113] | HQ | HQ | |
Tanzania | People with TB and traditional healers | Content analysis | 32 IDIs [114] | HQ | HQ | |
LMIC | Bangladesh | People with TB |
Qualitative analysis of open-ended survey questions |
229 interviews [115] | MQ | MQ |
People with TB and health care workers |
Qualitative analysis using apriori codes |
24 IDIs [116] | HQ | HQ | ||
Cambodia | People with TB, health care workers, and community volunteers | Thematic analysis | 43 IDIs and 6 FGDs [48] | MQ | HQ | |
People with TB and the general population | 13 FGDs [117] | HQ | HQ | |||
India | Health care workers | Thematic analysis | 16 IDIs [118] | HQ | HQ | |
People with TB |
Not presented in the article |
76 IDIs [119], 75 structured interviews [96] | MQ | MQ | ||
108 structured interviews [120] | MQ | HQ | ||||
Qualitative analysis of open-ended survey questions |
229 interviews [115] | MQ | MQ | |||
People with TB and health care workers |
Qualitative analysis using apriori codes |
19 IDIs [121] | MQ | HQ | ||
Thematic analysis | 71 IDIs [122] | HQ | HQ | |||
Indonesia | People with TB and community volunteers | Thematic analysis | 67 IDIs and 6 FGDs [123] | HQ | HQ | |
People with TB, TB survivors, village leaders, and community volunteers |
Not presented in the article |
50 IDIs and 3 FGDs [124] | HQ | HQ | ||
Nigeria | General population | Thematic analysis | 56 IDIs [125] | MQ | HQ | |
Philippines | People with TB and the general population | Thematic analysis | 22 IDIs and 3 FGDs [126] | HQ | HQ | |
Zambia | People with TB and community volunteers | Thematic analysis | 30 IDIs and 6 FGDs [127] | MQ | HQ | |
Zimbabwe | People with presumptive TB | Grounded theory | 20 IDIs [128] | HQ | HQ | |
UMIC | Brazil | Health care workers | Discourse analysis | 16 IDIs [129] | MQ | HQ |
People with TB | Content analysis | 23 IDIs [130] | MQ | HQ | ||
Thematic analysis | 7 IDIs [131] | MQ | HQ | |||
Discourse analysis | 7 IDIs [132] | HQ | MQ | |||
China | People with TB |
Qualitative analysis of open-ended survey questions |
70 interviews [133] | MQ | MQ | |
People with TB (migrants) | Thematic analysis | 34 IDIs [134] | MQ | HQ | ||
People with TB (migrants), People with presumptive TB, and health care workers |
Framework approach |
60 IDIs and 12 FGDs [135] | MQ | HQ | ||
People with TB, health care workers, policymakers, and community volunteers | Thematic analysis | 47 IDIs and 5 FGDs [136] | MQ | HQ | ||
Russia | People with TB | Grounded theory | 5 FGDs [137] | HQ | HQ | |
People with TB and health care workers |
32 IDIs and 11 participants in FGDs (number of FGDs not specified) [138] | HQ | HQ | |||
South Africa | Contacts of people with TB, health care workers, policymakers, and people with TB (miners) |
Thematic analysis and grounded theory |
104 applied ethnography using formal/informal IDIs, FGDs, field notes, and participant observations [139] | HQ | HQ | |
Health care workers, village leaders, and researchers |
Thematic analysis | 12 IDIs [140] | HQ | HQ | ||
People with TB | 41 IDIs [141] | MQ | HQ | |||
People with TB, contacts of people with TB, and health care workers | 25 IDIs and 4 FGDs [142] | HQ | HQ | |||
People with TB, the general population, and community volunteers | 93 reports from participatory research and participants observation [143] | HQ | HQ | |||
People with TB and general population |
Thematic analysis and grounded theory |
8 IDIs [144] | HQ | HQ | ||
Thailand | People with TB (migrants) and health care workers | Thematic analysis | 12 IDIs and 11 FGDs [145] | MQ | HQ |
Each number at the normal line of type in each cell referred to the sample size of each discrete study that shared the respective characteristics (country, study population, study design, and study quality). The number/s in bracket indicate the source article/s. Blank cells indicated that no studies of a particular set of characteristics were identified and included in this review
CASP critical appraisal skills program; FGD focus group discussions; HQ high quality, IDI in-depth interviews; LIC low-income countries, LMIC lower-middle-income countries, LQ low quality; MQ moderate quality, TB tuberculosis, UMIC upper-middle-income countries,
*Based on World Bank classification. Low-income economies—gross national income (GNI) per capita $1,025 or less in 2018; lower-middle-income economies—GNI per capita between $1,026 and $3,995; upper-middle-income economies—GNI per capita between $3,996 and $12,375
†Study quality was assessed using the Newcastle–Ottawa scale. The highest possible score for cross-sectional studies was 10 (5 for selection, 2 for comparability, and 3 for outcome). The highest possible score for case–control studies was 9 (4 for selection, 2 for comparability, and 3 for exposure). The highest possible score for cohort studies was 9 (4 for selection, 2 for comparability, and 3 for exposure). Studies that scored 0–3 were regarded as LQ, 4–6 were regarded as MQ, and ≥ 7 were regarded as HQ
‡All papers were pre-ranked (high, moderate, low), and the levels were adjusted according to the dependability and credibility of the findings. We pre-ranked all papers as high. The ranking remained high if the papers were regarded as dependable, and the findings were unequivocal. We downgraded the paper from high to moderate if the papers scored 3 or less in terms of dependability or scored a mix of unequivocal and credible in terms of credibility
§CASP for qualitative study had 10 questions to appraise the paper critically. We gave a score of 1 if the paper fulfilled a criterion, 0.5 if we could not tell if the paper fulfilled a criterion, and 0 if it did not fulfil a criterion. A score of 0–5 equated to LQ study, a score of 6–7 equated to MQ study, and a score of ≥ 8 equated to HQ study